A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2016
Price : $35 *
At a glance
- Drugs Sonidegib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker
- 20 Oct 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 05 May 2014 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 05 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.